The JAK inhibitor ruxolitinib reduces inflammation in an ILC3-independent model of innate immune colitis

por Overstreet, A.M., LaTorre, D.L., Abernathy-Close, L., Murphy, S.F., Rhee, L., Boger, A.M., Adlaka, K.R., Iverson, A.M., Bakke, D.S., Weber, C.R., Boone, D.L.
Publicado 2018